October 19, 2020 -- Samsung Biologics has entered into a strategic partnership with BioEleven to develop and manufacture BN-101A, a third-generation immunotherapy to treat cancer.
BN-101A blocks programmed cell death ligand 1 (PD-L1) function and promotes anti-cancer T- cell activity. The drug has been validated in preclinical models and BioEleven plans to enter a global phase I clinical trial by 2022.
Under the agreement, Samsung Biologics will provide the full scope of its development services including cell line development, process development, nonclinicial and clinical material manufacturing, and regulatory filing support.
Already have an account? Sign in Here
To access all ScienceBoard content create a free account now: